MedMira Reports Second Quarter Results

HALIFAX, April 1, 2013 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, reported today on its financial results for the three and six month periods ending January 31, 2013.

"During the second quarter, we continued to operate on a stabilized financial platform enabling many of the Company's business development and product commercialization activities to advance," said Daniel Frid, CFO, MedMira Inc.  "Our top line revenues increased over the same period in 2012 with revenue generation from services related to the Company's ongoing product development and commercialization contract with the US military."

Frid added, "We recorded a slight increase in operating expenses due to additional research expenses related to the US military contract.  This project continues to advance, with critical milestones being met as we progress towards the approval and launch of the new products."

Second Quarter Financial Highlights

• The Company recorded revenue from product sales and services in the quarter ended January 31, 2013 of $533,592 as compared to $274,188 for the same period last year. The increase in revenue was due to service revenue earned for research conducted for the US military contract.  Revenue from product sales was $255,787 as compared to $274,188 for the same period last year.
  
  
• Gross profit for the quarter was $159,814 compared to $210,956 in the same period in 2012.  The decrease in gross profit percentage to 30% from 77% was due to the lower margins on the US military service revenue than on product sales.  Gross profit on product sales alone was 55%.
  
  
• Total operating expenses increased to $714,630 in the quarter ended January 31, 2013, compared to $684,569 during the same period in 2012.  The increase in operating expenses was attributed to an increase in research costs related to the US military contract and marketing expenses related to the ongoing branding initiatives including a new corporate identity, redesigned website, and product promotional materials.
  
  
• The Company recorded an accounting gain of $1,718,484 due to the fair value remeasurement of its debt.  This change in accounting estimate was the result of changes in the fair value assumptions of the Company's debt.

About MedMira

MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's rapid flow-through HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities.  Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE MEDMIRA INC.

Copyright 2013 Canada NewsWire